Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Artemisinin-based combination therapy for ... - The Cochrane Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
4.2 Asia 3 836 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.53, 3.86]<br />
5 P. vivax parasitaemia 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
5.1 Mixed P. falciparum and<br />
vivax infection at baseline<br />
5 1279 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.57, 3.00]<br />
5.2 P. vivax parasitaemia by<br />
day 28<br />
1 208 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 3.88]<br />
5.3 P. vivax parasitaemia by<br />
day 42<br />
4 1003 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.21, 0.41]<br />
6 Gametocyte development (in<br />
those negative at baseline)<br />
3 883 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.54, 3.28]<br />
7 Gametocyte carriage 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
7.1 Gametocyte carriage day 0 1 294 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.10]<br />
7.2 Gametocyte carriage day 3 2 536 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.21, 1.48]<br />
7.3 Gametocyte carriage day 7 3 636 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.14, 0.85]<br />
7.4 Gametocyte carriage day<br />
14<br />
2 536 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.08, 2.10]<br />
8 Serious adverse events (including<br />
deaths)<br />
7 1773 Risk Ratio (M-H, Fixed, 95% CI) 2.96 [0.64, 13.76]<br />
9 Early vomiting 6 1479 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.55, 2.08]<br />
Comparison 7. Artesunate plus mefloquine vs Artesunate plus amodiaquine<br />
Outcome or subgroup title<br />
No. of<br />
studies<br />
No. of<br />
participants Statistical method Effect size<br />
1 Total Failure (P. falciparum) Day<br />
28 PCR unadjusted<br />
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
1.1 Africa 1 493 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.12, 2.46]<br />
2 Total Failure (P. falciparum) Day<br />
28 PCR adjusted<br />
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
2.1 Africa 1 482 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
3 Gametocyte carriage 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only<br />
3.1 Gametocyte carriage day 0 1 505 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
3.2 Gametocyte carriage day 3 1 505 Risk Ratio (M-H, Fixed, 95% CI) 17.31 [0.90, 332.99]<br />
3.3 Gametocyte carriage day 7 1 505 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
3.4 Gametocyte carriage day<br />
14<br />
1 505 Risk Ratio (M-H, Fixed, 95% CI) Not estimable<br />
<strong>Artemisinin</strong>-<strong>based</strong> <strong>combination</strong> <strong>therapy</strong> <strong>for</strong> treating uncomplicated malaria (Review)<br />
Copyright © 2009 <strong>The</strong> <strong>Cochrane</strong> Collaboration. Published by John Wiley & Sons, Ltd.<br />
114